

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT
STATE/TERRITORY: **DELAWARE**

METHODS AND STANDARDS FOR ESTABLISHING PAYMENT RATES –
OTHER TYPES OF CARE
REIMBURSEMENT FOR PHARMACEUTICALS

Reimbursement Policy:

The lower of Usual and Customary or Actual Acquisition Cost (AAC) for Drug Reimbursement is derived using the methodology in the table below.

Category	Ingredient Cost	Professional Dispensing Fee
Brand Drug	NADAC	\$10
Generic Drug	NADAC	\$10
Drugs Without NADAC	WAC for legend and WAC-2% for non-legend; or a Delaware Maximum Allowable Cost, whichever is lower.	\$10
340B Purchased Drug	AAC for dispensed drugs	\$10
	AAC for physician administered drugs	\$0
Contract 340B Pharmacy	Drugs acquired through the Federal 340B Drug Pricing Program and dispensed by 340B contract pharmacies are not covered.	N/A
Drugs purchased by 340B entities enrolled with DMMA as utilizing public health service products, which based on specific conditions, must purchase drugs outside of the 340B inventory when that drug is not available or eligible for 340B purchase.	NADAC	\$10
Federal Supply Schedule	AAC	\$10
Drugs Acquired at Nominal Price	AAC	\$10
Specialty Drugs-Mailed	AAC (Invoice price)	\$27
Drug Not Dispensed by Retail Pharmacy	NADAC or WAC, whichever is lower.	\$10
Physician Administered Drugs	AAC based on invoice price if maximum unit cost is greater than or equal to \$50. For drugs where the maximum cost is less than \$50, the cost will be based on direct price or Average Sales Price plus 6% the Medicare fee schedule.	N/A
Clotting Factor	AAC (Invoice Price)	\$27
Investigational Drugs (when prior authorized; as a general rule not covered products)	AAC	\$10

TN No.SPA#[~~17-002 23-0003~~]

Approval Date [~~June 2, 2017~~]

Supersedes

TN No. SPA#[~~397 17-002~~]

Effective Date [~~January 1, 2017~~ January 1, 2023]